Evidence map›Paper›PMID 22732882›Full record

ArticleMolecules (Basel, Switzerland)2012

Residue-ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S- and NH-DABOs as non-nucleoside reverse transcriptase inhibitors.

Monique Araújo de Brito, Carlos Rangel Rodrigues, José Jair Viana Cirino, Jocley Queiroz Araújo, Thiago Honório, Lúcio Mendes Cabral, Ricardo Bicca de Alencastro, Helena Carla Castro, Magaly Girão Albuquerque

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Comparative amino acid decomposition analysis of potent type I p38α inhibitors.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Monique Araújo de BritoLaboratory of Computational Medicinal Chemistry-LabQMC, Faculty of Pharmacy, Fluminense Federal University-UFF, Niterói, RJ 24241-000, Brazil. moniquebrito@id.uff.br
Carlos Rangel Rodrigues
José Jair Viana Cirino
Jocley Queiroz Araújo
Thiago Honório
Lúcio Mendes Cabral
Ricardo Bicca de Alencastro
Helena Carla Castro
Magaly Girão Albuquerque

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 74 dihydroalkoxybenzyloxopyrimidines (DABOs), a class of highly potent non-nucleoside reverse transcriptase inhibitors (NNRTIs), was retrieved from the literature and studied by receptor-dependent (RD) three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis to derive RD-3D-QSAR models. The descriptors in this new method are the steric and electrostatic interaction energies of the protein-ligand complexes (per residue) simulated by molecular dynamics, an approach named Residue-Ligand Interaction Energy (ReLIE). This study was performed using a training set of 59 compounds and the MKC-442/RT complex structure as reference. The ReLIE-3D-QSAR models were constructed and evaluated by genetic algorithm (GA) and partial least squares (PLS). In the best equations, at least one term is related to one of the amino acid residues of the p51 subunit: Asn136, Asn137, Glu138, and Thr139. This fact implies the importance of interchain interaction (p66-p51) in the equations that best describe the structure-activity relationship for this class of compounds. The best equation shows q² = 0.660, SE(cv) = 0.500, r² = 0.930, and SEE = 0.226. The external predictive ability of this best model was evaluated using a test set of 15 compounds. In order to design more potent DABO analogues as anti-HIV/AIDS agents, substituents capable of interactions with residues like Ile94, Lys101, Tyr181, and Tyr188 should be selected. Also, given the importance of the conserved Asn136, this residue could become an attractive target for the design of novel NNRTIs with improved potency and increased ability to avoid the development of drug-resistant viruses.

Indexed as

Quantitative Structure-Activity RelationshipAmino AcidsDatabases as TopicHIV-1Inhibitory Concentration 50LigandsModels, MolecularNucleosidesPyrimidinesReceptors, Cell SurfaceReverse Transcriptase InhibitorsRNA-Directed DNA PolymeraseThermodynamicsAmino AcidsLigandsNucleosidesPyrimidinesReceptors, Cell SurfaceReverse Transcriptase InhibitorsRNA-Directed DNA Polymerase

Identifiers

PMID22732882
PMCPMC6269006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.